Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 39 Carcinoma, Non-Small-Cell Lung 30 Esophageal Squamous Cell Carcinoma 23 Carcinoma, Hepatocellular 23 Triple Negative Breast Neoplasms 19 Breast Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 17 Advanced Solid Tumor 17 Melanoma 15 Stomach Neoplasms 14 Small Cell Lung Carcinoma 13 Colorectal Neoplasms 13 Uterine Cervical Neoplasms 12 Neoplasms 10 Carcinoma, Transitional Cell 10 Carcinoma, Renal Cell 10 Recurrence 9 Head and Neck Neoplasms 8 Solid Tumor 7 Sarcoma 7 Neoplasm Metastasis 7 Liver Neoplasms 7 Esophageal Neoplasms 6 Urinary Bladder Neoplasms 5 Rectal Neoplasms 5 Advanced Solid Tumors 5 Pancreatic Neoplasms 4 Nasopharyngeal Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4

Interventions

pembrolizumab 2 toripalimab 1 sintilimab 1 pemigatinib 1 osimertinib 1 durvalumab 1 Vinorelbine 1 Platinum Compounds 1 Nivolumab 1 Ipilimumab 1 Drug Therapy 1 AZD 6244 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Non Small Cell Lung Cancer × toripalimab × Clear all

NCT04144608 2024-08-09

TOGATHER

Hunan Province Tumor Hospital

Phase 2 Completed

Advanced Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡